Ozurdex

This page shows the latest Ozurdex news and features for those working in and with pharma, biotech and healthcare.

NICE backs Bayer's Eylea in diabetic eye condition

TheInstitute also recommends Allergan's Ozurdex in final guidance. Bayer's Eylea and Allergan's Ozurdex have been recommended for use on the NHS in England to treat diabetic macular oedema ... Meanwhile, NICE also recommended the use of Allergan's

Latest news

NICE recommends Ozurdex for diabetic eye condition

The preliminary recommendations cite the implant, marketed by Allergan as Ozurdex, as a treatment option in patients where the implant is to be used in an eye with an intraocular (pseudophakic) ... Ozurdex is injected into the eye once every six months
Fresh approval for Roche's Lucentis as competition heats up

Roche's drug is being challenged in the market by Bayer's Eylea (aflibercept) as well as newer entrants such as Allergan's Ozurdex (intravitreal dexamethasone).
New eye indication for Allergan’s Ozurdex

The European Commission granted marketing authorisation to Ozurdex, an eye implant that contains the corticosteroid dexamethasone, as a treatment for adults with visual impairment due to diabetic macular oedema (DMO). ... Ozurdex joins a competitive
Allergan will start phase III DARPin trials next year

On the plus side, Allergan said the FDA had approved a new indication for its intravitreal implant Ozurdex (dexamethasone), namely the treatment of diabetic macular oedema (DME) in adults who have
NICE against new indication for Novartis' Lucentis

Its draft guidance concluded the ICER for Lucentis in central RVO versus Allergan's Ozurdex (dexamethasone) intravitreal implant, the currently approved treatment, was likely to be over £37, 400 per QALY ... Ozurdex was recommended by NICE earlier this

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

Allergan and taking a specialised approach

spasticity associated with stroke and for the ophthalmology treatment Ozurdex in diabetic macular oedema.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Medical Writer: Salary TBC

Project Manager/ Account Manager: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Senior Medical Writer: Up to £50, 000 with Benefits

Account Director, Healthcare Marketing Agency: Salary TBC

AD – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Project/ Events Manager – Medical Education and Events Agency: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

PR Director – Health & Wellbeing – Mat Cover (4 days a week)...: Salary TBC

Account Director, Medical Education: Salary TBC

Account/ Project Director – Medical Affairs – Surrey: Salary TBC

Digital Account Director: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Planner – Healthcare Advertising – New Role: Salary TBC

Senior Medical Writer: Great salary and benefits

Subscribe to our email news alerts

PMHub

Add my company

COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

The importance of co-creation with patients: Overcoming the barriers...
Three billboards on the road to multichannel: Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence: Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....